Business Context and Reporting Period
This Form 8-K, dated January 27, 2025, reports on Drugs Made In America Acquisition Corp., a Cayman Islands-based special purpose acquisition company (SPAC). The filing details the consummation of the Company's Initial Public Offering (IPO) on January 29, 2025, following the effectiveness of the registration statement on January 7, 2025, and a post-effective amendment on January 27, 2025.
Key Financial Metrics
- IPO Proceeds: The Company sold 20,000,000 Units at $10.00 per Unit, generating gross proceeds of $200,000,000.
- Private Placement Proceeds: Simultaneously, the Company sold 400,000 Private Units to the Sponsor at $10.00 per Unit, generating $4,000,000.
- Total Capital Raised: $204,000,000 (Gross).
- Trust Account: $201,000,000 of net proceeds from the IPO and Private Placement were deposited into a trust account for public shareholders.
- Over-Allotment Option: Underwriters were granted a 45-day option to purchase up to 3,000,000 additional Units.
- Operating Metrics: The filing does not provide revenue, profit, cash flow, or margin data as the Company is a pre-business combination SPAC.
Material Changes
The primary material change is the transition from a private entity to a publicly traded company on The Nasdaq Stock Market LLC. The Company now has three classes of securities registered: Units (DMAAU), Ordinary Shares (DMAA), and Rights (DMAAR). Additionally, the Company adopted its Second Amended and Restated Memorandum and Articles of Association in connection with the IPO.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use the proceeds to consummate an initial business combination. An audited balance sheet reflecting the IPO proceeds will be filed within four business days of consummation.
Restrictions and Contingencies:
- Private Units Lock-up: Holders of Private Units agreed not to transfer them until the earlier of six months after the initial business combination or the date the share price exceeds $12.50 for 20 trading days within a 30-day period (for 50% of units).
- Liquidity: The Company's liquidity is currently dependent on the funds held in the trust account and the Private Placement proceeds.
Investor Verification Checklist
- Verify the final audited balance sheet to be filed within four business days of January 29, 2025, to confirm the exact net proceeds and cash position.
- Review the Underwriting Agreement (Exhibit 1.1) for details on underwriting discounts and the status of the 45-day over-allotment option.
- Confirm the specific terms of the Investment Management Trust Agreement (Exhibit 10.2) regarding interest earnings and withdrawal conditions.
- Monitor the trading status of the Units (DMAAU) and the subsequent separation into Ordinary Shares (DMAA) and Rights (DMAAR).